Orexin 2 receptor–selective agonist danavorexton improves narcolepsy phenotype in a mouse model and in human patients
Sign Up to like & getrecommendations! Published in 2022 at "Proceedings of the National Academy of Sciences of the United States of America"
DOI: 10.1073/pnas.2207531119
Abstract: Significance Despite the discovery of the orexin (hypocretin) neuropeptides in 1998 and their role in narcolepsy type 1 (NT1), current pharmacotherapy addresses only the associated symptoms and not the underlying loss of orexin. Danavorexton (TAK-925)… read more here.
Keywords: orexin; danavorexton; mouse; selective agonist ... See more keywords